Non-Invasive, Self-Neuromodulation, Adjunct to Standard of Care Therapy Using Amygdala Derived EEG-fMRI Pattern Biomarkers to Help Patients with PTSD
HAIFA, Israel – March 21, 2023 – GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental disorders, announced today that it has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its flagship…
QMHMaster1
Just Six Months After Awarding GrayMatters Health a Grant of €2.5M, the EIC Demonstrates Vote of Confidence with Equity Investment in the Company
HAIFA, Israel – March 20, 2023 – GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental disorders, announced today that the European Innovation Council (EIC) Fund, following the September 2022 grant…
HAIFA, Israel – September 13 2022 – GrayMatters Health (GMH), developer of digital self-neuromodulation therapeutics for mental disorders, announced today that it has been named as a Falling Walls Top 25 Venture winner. The award recognizes the most promising science start-ups and innovations and technologies across their respective industries.
As one of the…
HAIFA, Israel – September 7, 2022 – GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental disorders, has been awarded a €2.5 million grant from the European Innovation Council (EIC) to accelerate the development of Prism for PTSD, a non-invasive digital therapy, to be used as an adjunct to standard of care (SOC) treatments…
Investment Led by Otsuka Medical Devices
HAIFA, Israel, Jan. 11, 2022 /PRNewswire/ -- GrayMatters Health (GMH) developer of digital self-neuromodulation therapeutics for mental disorders, announced today the successful closing of its $10 million Series A financing round. Otsuka Medical Devices Co., Ltd. (OMD) was the lead investor in this round. In addition to its investment, OMD obtained certain rights with regard…